Recently, a phase I/II trial (University Hospital Medical Information Network, Japan—000027279) on HNSCC used a WT1 peptide-loaded DC vaccine and OK-432 adjuvant in combination with conventional chemotherapy, and demonstrated its feasibility, safety, and reasonable clinical efficacy in patients of R/M HNSCC [113]. This evidence concerns the gene WT1 and head and neck squamous cell carcinoma.